Industry update: March 2021
15 May 2020
With dozens of medicinal cannabis plays now listed on the ASX and with many pretenders along for the ride, the serious exponents need to offer investors more than opaque promises about exploiting the healing herb.
This is ever more the case given the so-called ‘green gold’ is at risk of becoming a commoditised market – especially in jurisdictions such as the US where recreational pot is widely legalised.
So how do the genuine players stand out above the canopy of chancers?
Little Green Pharma (ASX:LGP) has some genuine pioneering notches on its belt.
The Perth-based outfit was the first to produce a home-grown medicinal cannabis product for patient use (in August 2018) and it was also the first to export when it became legal to do so.
“Even today we are the only local producer among the 130 products available,” says LGP founder and CEO Fleta Solomon.
“There are lots of licences issued and a lot of people growing, but no-one has actually produced the finished medicines.”
LGP is also generating meaningful revenue: a unicorn-type rarity in the sector.
Read the full article here: https://www.sharecafe.com.au/2020/05/15/little-green-pharma-stands-out-amid-the-crowded-cannabis-canopy/
We have been granted a new manufacturing permit from the Office of Drug Control. Read more...
Little Green Pharma have sponsored a new digital platform, GreenChoices to provide both medical practitioners and patients with meaningful research and education, with the aim of assisting them make informed choices about medical cannabis as a possible treatment option.